FDA OKs Novel Dual-Action Stimulant Med for ADHD FDA OKs Novel Dual-Action Stimulant Med for ADHD

Azstarys combines extended-release serdexmethylphenidate and immediate-release dexmethylphenidate and is expected to provide steady ADHD symptom control.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Psychiatry News Source Type: news